Drug Trial Radar · NCT07257627
Comparative PK/PD of Single-Dose THDB0206 at Different Injection Sites
Last checked: Nov 19, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Apr 17, 2024
Primary completion
Dec 2, 2024
Study completion Dec 2, 2024
Sponsor
- Lead sponsor
- Tonghua Dongbao Pharmaceutical Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This open-label, randomized, three-period crossover, 8-hour hyperinsulinemic-euglycemic clamp study will compare the pharmacokinetic and pharmacodynamic profiles of THDB0206 after single subcutaneous administration at different injection sites in healthy Chinese adults.
Conditions
- Healthy Participants
Interventions
THDB0206 injection-Upper armDrug
Subjects received a single subcutaneous injection of THDB0206 at a dose of 0.2 U/kg in the upper arm.
THDB0206 Injection-AbdomenDrug
Subjects received a single subcutaneous injection of THDB0206 at a dose of 0.2 U/kg in the abdomen.
THDB0206 Injection-ThighDrug
Subjects received a single subcutaneous injection of THDB0206 at a dose of 0.2 U/kg in the thigh.
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUCLisp(0-inf)Time frame: From 0 to 8 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.